Latest Clinical Trials
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer Nancy Lin, MD NA
COMPLETED
(Sep 1, 2026)
PHASE1 Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib ARCAGY/ GINECO GROUP NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC Dana-Farber Cancer Institute NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma Harry H Yoon NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) Boston Scientific Corporation NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) BioInvent International AB NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC The First Affiliated Hospital of Bengbu Medical University NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE1 CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer National Cancer Institute (NCI) NA
SUSPENDED
(Sep 1, 2026)
PHASE1 Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) Alliance for Clinical Trials in Oncology NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies Institut de Recherches Internationales Servier NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer Hoffmann-La Roche NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer BioNTech SE NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer Hutchmed NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort Boston Scientific Corporation NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) PanTher Therapeutics NA
RECRUITING
(Sep 1, 2026)
PHASE1 An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer ToLymph Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE2 DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer Elizabeth Stover, MD, PhD NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors Jiangsu HengRui Medicine Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer Genmab NA
RECRUITING
(Sep 1, 2026)
PHASE3 Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer Massachusetts General Hospital NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) Puma Biotechnology, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE2 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Revolution Medicines, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas Gilead Sciences NA
RECRUITING
(Sep 1, 2026)
PHASE2 Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Immuneering Corporation NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers CSPC Megalith Biopharmaceutical Co.,Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers AbbVie NA
RECRUITING
(Sep 1, 2026)
PHASE2 GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC West China Hospital NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma. Gustave Roussy, Cancer Campus, Grand Paris NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC Shaodong Hong NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) University of Maryland, Baltimore NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) Fudan University NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 ATEMPT 2.0: Adjuvant T-DM1 vs TH Dana-Farber Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE2 Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer National Cancer Institute (NCI) NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) Compass Therapeutics NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Phase I Intravesical PPM Therapy for NMIBC VA Office of Research and Development NA
RECRUITING
(Aug 1, 2026)
PHASE1 Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial National Cancer Institute (NCI) NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients Fudan University NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer Barbara Ann Karmanos Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE2 Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Innovent Biologics (Suzhou) Co. Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer Henan Cancer Hospital NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue Pfizer NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer Nanjing Leads Biolabs Co.,Ltd NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study Qilu Hospital of Shandong University NA
RECRUITING
(Aug 1, 2026)
PHASE2 FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors Fate Therapeutics NA
RECRUITING
(Aug 1, 2026)
PHASE1 Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Corcept Therapeutics NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) GlaxoSmithKline NA
RECRUITING
(Aug 1, 2026)
PHASE3 Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer ImmunityBio, Inc. NA
WITHDRAWN
(Aug 1, 2026)
PHASE1 A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc NA
RECRUITING
(Aug 1, 2026)
PHASE3 Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study Zhejiang Cancer Hospital NA
RECRUITING
(Aug 1, 2026)
PHASE2 Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations Jacobio Pharmaceuticals Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) Sichuan Baili Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study Liu Shu NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer Harbin Medical University NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) M.D. Anderson Cancer Center NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer ARCAGY/ GINECO GROUP NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel Sironax USA, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer Beijing Gene Key Life Technology Co., Ltd NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis Zhejiang Cancer Hospital NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status Barbara Ann Karmanos Cancer Institute NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma Revolution Medicines, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE3 Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer The First Affiliated Hospital of Zhengzhou University NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer The First Affiliated Hospital with Nanjing Medical University NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer University Health Network, Toronto NA
COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2 Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor Washington University School of Medicine NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours AstraZeneca NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax M.D. Anderson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma RS Oncology LLC NA
COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2 ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer Amplia Therapeutics Limited NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) Phanes Therapeutics NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC Bruno Bockorny NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy Immutep S.A.S. NA
TERMINATED
(Jul 1, 2026)
PHASE2, PHASE3 A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Daiichi Sankyo NA
RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma M.D. Anderson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors OHSU Knight Cancer Institute NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC Biotheus Inc. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) Gilead Sciences NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis Ruijin Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers Corcept Therapeutics NA
RECRUITING
(Jul 1, 2026)
PHASE2 Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer Yukinori Ozaki NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE3 Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) AstraZeneca NA
RECRUITING
(Jul 1, 2026)
PHASE3 Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer Peking Union Medical College Hospital NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer AstraZeneca NA
RECRUITING
(Jul 1, 2026)
PHASE3 A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer BioNTech SE NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) GlaxoSmithKline NA
RECRUITING
(Jul 1, 2026)
PHASE3 A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer Theriva Biologics SL NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as Second-line Treatment for Advanced Biliary Tract Cancer: a Phase Ⅱ Clinical Trial Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
COMPLETED
(Jul 1, 2026)
PHASE2 Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer University of Oklahoma NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) Eddingpharm (Zhuhai) Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer The First Hospital of Jilin University NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) University of Iowa NA
COMPLETED
(Jun 1, 2026)
PHASE2 Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer Golden Biotechnology Corporation NA
COMPLETED
(Jun 1, 2026)
PHASE1, PHASE2 Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] University of Texas Southwestern Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer Ira Winer NA
RECRUITING
(Jun 1, 2026)
PHASE2 Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer Anne Noonan NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 University of Rochester NA
RECRUITING
(Jun 1, 2026)
PHASE1 A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors Institut Paoli-Calmettes NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis National Cancer Institute (NCI) NA
COMPLETED
(Jun 1, 2026)
PHASE2 A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer Agenus Inc. NA
COMPLETED
(Jun 1, 2026)
PHASE2 BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia SillaJen, Inc. NA
RECRUITING
(Jun 1, 2026)
PHASE1 Proglumide and Chemotherapy for Metastatic Pancreatic Cancer Georgetown University NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer Hebei Medical University Fourth Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE2 A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy Boehringer Ingelheim NA
TERMINATED
(Jun 1, 2026)
PHASE1 Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients National Cancer Center, Japan NA
RECRUITING
(Jun 1, 2026)
PHASE2 Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. Grupo Español de Tratamiento de Tumores de Cabeza y Cuello NA
RECRUITING
(Jun 1, 2026)
PHASE2 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC Dartmouth-Hitchcock Medical Center NA
RECRUITING
(Jun 1, 2026)
PHASE2 BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma Mayo Clinic NA
RECRUITING
(Jun 1, 2026)
PHASE2 IBI343 in Combination Therapy for Advanced Malignant Solid Tumors Innovent Biologics (Suzhou) Co. Ltd. NA
RECRUITING
(Jun 1, 2026)
PHASE2 A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer Sichuan Baili Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer University Health Network, Toronto NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies The First Affiliated Hospital with Nanjing Medical University NA
RECRUITING
(Jun 1, 2026)
PHASE2 SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer Shandong Cancer Hospital and Institute NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer Ruijin Hospital NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer The First Affiliated Hospital of Zhengzhou University NA
RECRUITING
(Jun 1, 2026)
PHASE2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer City of Hope Medical Center NA
COMPLETED
(May 1, 2026)
PHASE2 A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer NewLink Genetics Corporation NA
TERMINATED
(May 1, 2026)
PHASE1, PHASE2 Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer University College, London NA
COMPLETED
(May 1, 2026)
PHASE2 A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer Changchun GeneScience Pharmaceutical Co., Ltd. NA
COMPLETED
(May 1, 2026)
PHASE1, PHASE2 A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Arcus Biosciences, Inc. NA
COMPLETED
(May 1, 2026)
PHASE1 Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Daiichi Sankyo NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology M.D. Anderson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma Chang Gung Memorial Hospital NA
RECRUITING
(May 1, 2026)
PHASE1 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001) Innovent Biologics (Suzhou) Co. Ltd. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer Wuhan YZY Biopharma Co., Ltd. NA
COMPLETED
(May 1, 2026)
PHASE1, PHASE2 A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) Lyvgen Biopharma Holdings Limited NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Arcus Biosciences, Inc. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma Washington University School of Medicine NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients Tango Therapeutics, Inc. NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Study of Surgery and Radiotherapy in People With Breast Cancer Memorial Sloan Kettering Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer The First Affiliated Hospital with Nanjing Medical University NA
RECRUITING
(May 1, 2026)
PHASE2 Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms Ohio State University Comprehensive Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease. Nelum Corp NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors Health Hope Pharma NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer Jiangsu Cancer Institute & Hospital NA
RECRUITING
(May 1, 2026)
PHASE2 Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 FID-007 in Treating Participants With Advanced Solid Tumors University of Southern California NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment Shanghai Junshi Bioscience Co., Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE3 Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer Japanese Foundation for Cancer Research NA
COMPLETED
(Apr 1, 2026)
PHASE3 Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Faeth Therapeutics NA
TERMINATED
(Apr 1, 2026)
PHASE1 HCW9218 for Advanced Pancreatic Cancer ImmunityBio, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy Qilu Hospital of Shandong University NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma Ashish Manne NA
RECRUITING
(Apr 1, 2026)
PHASE2 Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer NRG Oncology NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) Yonsei University NA
RECRUITING
(Apr 1, 2026)
PHASE2 Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients Trishula Therapeutics, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE2 A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation Tyligand Pharmaceuticals (Suzhou) Limited NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma NovoCure Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE2 A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. Shanghai Jiaolian Drug Research and Development Co., Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE2 MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Marker Therapeutics, Inc. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1 PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer Biotheus Inc. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer University of California, San Diego NA
RECRUITING
(Apr 1, 2026)
PHASE1 Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) NA
RECRUITING
(Apr 1, 2026)
PHASE1 JS207 Combination Therapy in Triple-negative Breast Cancer Shanghai Junshi Bioscience Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE2 Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy Damanhour University NA
COMPLETED
(Apr 1, 2026)
PHASE2 Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2) Tianjin Medical University Cancer Institute and Hospital NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase Fudan University NA
RECRUITING
(Apr 1, 2026)
PHASE2 LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study Ruijin Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE2 A 2-part Phase 1/2 Open-label Trial on ODM-212 Orion Corporation, Orion Pharma NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer Henan Cancer Hospital NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas Centre Oscar Lambret NA
COMPLETED
(Mar 1, 2026)
PHASE2 Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer NewLink Genetics Corporation NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts Milton S. Hershey Medical Center NA
TERMINATED
(Mar 1, 2026)
PHASE3 CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer Canadian Cancer Trials Group NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Study of DF1001 in Patients With Advanced Solid Tumors Dragonfly Therapeutics NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer Sun Yat-sen University NA
COMPLETED
(Mar 1, 2026)
PHASE2 A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer iOnctura NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer University of California, Davis NA
RECRUITING
(Mar 1, 2026)
PHASE1 Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Chipscreen Biosciences, Ltd. NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer Shandong Tumor Hospital NA
RECRUITING
(Mar 1, 2026)
PHASE2 Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma Xiuchao Wang NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer Sun Yat-sen University NA
RECRUITING
(Mar 1, 2026)
PHASE2 
